Program
lutropin alfa
Also written as “Follitropin alfa/lutropin alfa (MBJ-0011)”, “Follitropin alfa/lutropin alfa” and “Luveris”.
Its studies are mostly in Infertility · Hypogonadism, led by Merck KGaA, Darmstadt, Germany.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 91 open or running | phase 4since May 20, 2006 | May 20, 2006 | Sep 30, 2027phase 3 · NCT07340827 |
Also a collaborator on its studies: Merck Serono Middle East FZ, Merck, S.L., Spain and Merck Pte. Ltd., Singapore.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2006First study: phase 4 study in HypogonadismFirst studyNCT00328926 · 11 enrolled · United States
- Feb 24, 2010Phase 2 study in InfertilityNCT01075815 · 76 enrolled · Spain
- Mar 2, 2010Phase 2 study in InfertilityNCT01079949 · 93 enrolled · Spain
- Mar 4, 2010Phase 3 study in HypogonadismNCT01084265 · 31 enrolled · China
- May 10, 2010Phase 3 study in InfertilityNCT01121991 · 55 enrolled
- Dec 20, 2011Phase 3 study in InfertilityNCT01497197 · 174 enrolled · United Arab Emirates
- May 19, 2021Phase 1 study in InfertilityNCT04899193 · 72 enrolled · China
- Nov 17, 2025Phase 1 study in InfertilityNCT07269327 · 24 enrolled · United Kingdom
- Jan 6, 2026Phase 3 study in InfertilityNCT07340827 · 266 planned · Japan
Ahead
- Sep 30, 2027Primary completion: phase 3 study in InfertilityNCT07340827
TargetBeta
“Luteinizing hormone/Choriogonadotropin receptor agonist”ChEMBL 37, by rule
Other programs on LHCGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Chorionic Gonadotropinrule | Organon | phase 4 | 4 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07340827Infertility · Japan | 3 | Recruiting | Sep 30, 2027 | 266 |
| NCT07269327Infertility · United Kingdom | 1 | Completed | Mar 9, 2026 | 24 |
| NCT04899193Infertility · China | 1 | Completed | May 28, 2022 | 72 |
| NCT01497197Infertility · United Arab Emirates | 3 | Terminated | Jan 2014 | 174 |
| NCT01121991Infertility | 3 | Completed | Sep 2005 | 55 |
| NCT01084265Hypogonadism · China | 3 | Completed | Dec 2005 | 31 |
| NCT01079949Infertility · Spain | 2 | Terminated | Oct 2010 | 93 |
| NCT01075815Infertility · Spain | 2 | Terminated | Oct 2010 | 76 |
| NCT00328926Hypogonadism · United States | 4 | Terminated | May 2012 | 11 |
How it is read
Names in the registry
- “Follitropin alfa/lutropin alfa (MBJ-0011)”, 1 entry
- “Follitropin alfa/lutropin alfa”, 1 entry
- “Luveris”, 1 entry
- “Luveris®”, 1 entry
- “r-hLH + r-hFSH”, 1 entry
Conditions, from the studies’ own filings
- Infertility, 7 studies
- Hypogonadism, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.